Director's Interest in Shares

RNS Number:0163M
Arana Therapeutics Limited
17 January 2008


For Immediate Release                                         17 January 2008


                             ARANA THERAPEUTICS LTD


            Grant of Shares to Director Under Performance Share Plan


Arana Therapeutics Ltd, (LSE: AAHx ASX:AAH) ("Arana" or the "Company"), the
Australian biopharmaceutical company, formed through the merger of Peptech and
EvoGenix in August 2007. The Company uses superior technology to develop next
generation drugs that will improve the lives of patients with inflammatory
diseases and cancer. The Company announced today that Dr Phil Jennings, a
director of the Company, has been granted 31,694 ordinary shares of no par value
in the capital of the Company at a price of nil per share under the Performance
Share Plan as approved by Shareholders at the Annual General Meeting held in
February 2005.

+----------+---------+---------+---------+-------------+-----------------+
|Director  |Direct or|No. of   |Date     |Consideration|Subsequent       |
|          |Indirect |Shares   |Granted  |(A$)         |beneficial       |
|          |Interest |Granted  |         |             |holding          |
+----------+---------+---------+---------+-------------+-----------------+
|Phil      |Direct   |31,694   |15       |Nil          |6,135 (indirect  |
|Jennings  |         |         |January  |             |interest)        |
|          |         |         |2008     |             |                 |
|          |         |         |         |             |                 |
|          |         |         |         |             |67,317 (direct   |
|          |         |         |         |             |interest)        |
|          |         |         |         |             |                 |
|          |         |         |         |             |                 |
+----------+---------+---------+---------+-------------+-----------------+
|          |         |         |         |             |                 |
+----------+---------+---------+---------+-------------+-----------------+


As a consequence of this grant, the total number of shares of Arana held by Dr
Jennings represents less than 0.1% of the issued share capital.



For further information, please contact:

Arana Therapeutics Ltd
Dr John Chiplin, Chief Executive Officer      [phone]
Niall Henderson, Chief Financial Officer      [phone]

Buchanan Communications
Lisa Baderoon ([e-mail])         [phone]
Rebecca Skye Dietrich / Catherine Breen

Nomura Code Securities
Charles Walker                                [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RDSDGGMMDNZGRZM